Desmoid tumour: the decisions you may face

Cancer page →Second-opinion finder →

3 treatment settings, 2 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

Advanced, first line

Newly diagnosed, asymptomatic or minimally symptomatic

2 options

Active surveillance with MRI at 1 to 2 months, then every 3 to 6 months; treat only on progression or symptoms.

Guideline

NCCN · Category 2A (observation)

The options, in plain words

Active surveillanceStandard of care

For low-risk prostate cancer, monitoring with PSA, MRI, and repeat biopsy instead of treating, because most such cancers never cause harm.

Avoids incontinence and erectile dysfunction of treatment in men who would never be harmed
Level-1 evidence of safety (ProtecT)

MRIStandard of care

MRI uses a strong magnet and radio waves, with no ionising radiation, to picture soft tissue in finer contrast than CT, so it is the standard scan for brain tumours, prostate, rectal cancer staging, liver lesions and breast screening in high-risk women. It is slow, expensive and blurred by movement.

No ionising radiation
Best soft-tissue and brain imaging
Functional sequences (diffusion, perfusion)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Active surveillance

Anxiety and adherence
Repeat biopsies
Under-used outside high-income countries

MRI

Slow and expensive
Motion artefacts
Gadolinium concerns in renal impairment

Questions to ask about this decision

Between Active surveillance and MRI, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (Desmoid Tumor Working Group consensus (Eur J Cancer 2020); NCCN Soft Tissue Sarcoma), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (newly diagnosed, asymptomatic or minimally symptomatic), which of the standard options do you recommend and why?
Why: Guideline options include: Active surveillance with MRI at 1 to 2 months, then every 3 to 6 months; treat only on progression or symptoms.

Add these to your appointment list, or take the full question set for this cancer.

Second line

Progressive or symptomatic disease

3 optionsCompare side by side →

Nirogacestat (DeFi) or sorafenib (Alliance A091105); alternatives include methotrexate-vinblastine, vinorelbine, anthracycline-based chemotherapy for rapidly progressive disease, and cryoablation for accessible extra-abdominal tumours.

Guideline

NCCN · Category 1 (nirogacestat), Category 2A (sor…

The options, in plain words

NirogacestatApprovedSmall-molecule gamma-secretase inhibitor

Nirogacestat is the first approved medicine for desmoid tumours, locally invasive growths that do not spread but can be crippling; it works by blocking Notch signalling.

SorafenibApprovedSmall-molecule multi-kinase inhibitor (VEGFR, PDGFR, RAF)

The first drug ever to extend life in advanced liver cancer (2007), now mostly a comparator arm that newer combinations are measured against.

MethotrexateApprovedAntifolate (DHFR inhibitor)

The 1948 antifolate that produced the first chemotherapy remissions in childhood leukaemia and the first cure of a solid tumour; still essential in ALL, lymphoma, osteosarcoma and CNS lymphoma.

The evidence behind it

DeFi Phase 3 NCT03785964 2022142 peopleevidence 75
Tests Nirogacestat
Progressing desmoid tumours: nirogacestat vs placebo
PFS HR 0.29; ORR 41% vs 8%.

The main trade-offs on record

Sorafenib all recorded rates →

Take without food (1 hour before or 2 hours after).
Possible QT prolongation. Check ECG and electrolytes; review other QT-prolonging drugs.

Methotrexate all recorded rates →

High-dose methotrexate requires normal renal function, hydration, urine alkalinisation and leucovorin rescue with level monitoring.

Questions to ask about this decision

Between Nirogacestat, Sorafenib and Methotrexate, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
How closely do I match the people in DeFi, and does that change what the results mean for me?
Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Soft Tissue Sarcoma), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (progressive or symptomatic disease), which of the standard options do you recommend and why?
Why: Guideline options include: Nirogacestat (DeFi) or sorafenib (Alliance A091105); alternatives include methotrexate-vinblastine, vinorelbine, anthracycline-based chemotherapy for rapidly progressive disease, and cryoablation for accessible extra-abdominal tumours.
Am I a candidate for Nirogacestat, Sorafenib, Methotrexate, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of DeFi apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Surgery

One path named

Reserved for selected abdominal wall tumours or complications (bowel obstruction, fistula); margins do not reliably predict recurrence.

The path, in plain words

Limb-salvage surgery and endoprosthetic reconstructionStandard of care

Removing a bone or soft-tissue sarcoma while keeping the arm or leg, rebuilding with metal implants, bone grafts or growing prostheses in children.

Preserves function without compromising survival
Custom implants for pelvis and spine

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Limb-salvage surgery and endoprosthetic reconstruction

Implant infection and mechanical failure over decades
Requires specialist sarcoma centres

Questions to ask about this decision

Is Limb-salvage surgery and endoprosthetic reconstruction the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (surgery), which of the standard options do you recommend and why?
Why: Guideline options include: Reserved for selected abdominal wall tumours or complications (bowel obstruction, fistula); margins do not reliably predict recurrence.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.

Living with cancer·Standard of care

Desmoid tumour: the decisions you may face

Cancer page →Second-opinion finder →

Advanced, first line

Newly diagnosed, asymptomatic or minimally symptomatic

2 options

Active surveillance with MRI at 1 to 2 months, then every 3 to 6 months; treat only on progression or symptoms.

Guideline

NCCN · Category 2A (observation)

The options, in plain words

Active surveillanceStandard of care

For low-risk prostate cancer, monitoring with PSA, MRI, and repeat biopsy instead of treating, because most such cancers never cause harm.

Avoids incontinence and erectile dysfunction of treatment in men who would never be harmed
Level-1 evidence of safety (ProtecT)

MRIStandard of care

No ionising radiation
Best soft-tissue and brain imaging
Functional sequences (diffusion, perfusion)

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Active surveillance

Anxiety and adherence
Repeat biopsies
Under-used outside high-income countries

MRI

Slow and expensive
Motion artefacts
Gadolinium concerns in renal impairment

Questions to ask about this decision

Between Active surveillance and MRI, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (Desmoid Tumor Working Group consensus (Eur J Cancer 2020); NCCN Soft Tissue Sarcoma), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (newly diagnosed, asymptomatic or minimally symptomatic), which of the standard options do you recommend and why?
Why: Guideline options include: Active surveillance with MRI at 1 to 2 months, then every 3 to 6 months; treat only on progression or symptoms.

Add these to your appointment list, or take the full question set for this cancer.

Second line

Progressive or symptomatic disease

3 optionsCompare side by side →

Guideline

NCCN · Category 1 (nirogacestat), Category 2A (sor…

The options, in plain words

NirogacestatApprovedSmall-molecule gamma-secretase inhibitor

Nirogacestat is the first approved medicine for desmoid tumours, locally invasive growths that do not spread but can be crippling; it works by blocking Notch signalling.

SorafenibApprovedSmall-molecule multi-kinase inhibitor (VEGFR, PDGFR, RAF)

The first drug ever to extend life in advanced liver cancer (2007), now mostly a comparator arm that newer combinations are measured against.

MethotrexateApprovedAntifolate (DHFR inhibitor)

The 1948 antifolate that produced the first chemotherapy remissions in childhood leukaemia and the first cure of a solid tumour; still essential in ALL, lymphoma, osteosarcoma and CNS lymphoma.

The evidence behind it

DeFi Phase 3 NCT03785964 2022142 peopleevidence 75
Tests Nirogacestat
Progressing desmoid tumours: nirogacestat vs placebo
PFS HR 0.29; ORR 41% vs 8%.

The main trade-offs on record

Sorafenib all recorded rates →

Take without food (1 hour before or 2 hours after).
Possible QT prolongation. Check ECG and electrolytes; review other QT-prolonging drugs.

Methotrexate all recorded rates →

High-dose methotrexate requires normal renal function, hydration, urine alkalinisation and leucovorin rescue with level monitoring.

Questions to ask about this decision

Between Nirogacestat, Sorafenib and Methotrexate, which do you recommend for me, and what about my case would make you choose differently?
Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
How closely do I match the people in DeFi, and does that change what the results mean for me?
Why: Trial populations are selected; age, fitness, prior treatment and biomarkers all affect how far results carry.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
Does your recommendation follow the current guideline (NCCN Soft Tissue Sarcoma), and if it departs from it, why?
Why: Departures from guidelines are sometimes right for an individual; they should be explained.
For my situation (progressive or symptomatic disease), which of the standard options do you recommend and why?
Why: Guideline options include: Nirogacestat (DeFi) or sorafenib (Alliance A091105); alternatives include methotrexate-vinblastine, vinorelbine, anthracycline-based chemotherapy for rapidly progressive disease, and cryoablation for accessible extra-abdominal tumours.
Am I a candidate for Nirogacestat, Sorafenib, Methotrexate, and what side effects should I expect?
Why: Knowing the expected toxicities helps you plan work, family, and supportive care.
How do the results of DeFi apply to someone like me?
Why: Trial populations differ from individual patients; ask how closely you match.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Surgery

One path named

Reserved for selected abdominal wall tumours or complications (bowel obstruction, fistula); margins do not reliably predict recurrence.

The path, in plain words

Limb-salvage surgery and endoprosthetic reconstructionStandard of care

Removing a bone or soft-tissue sarcoma while keeping the arm or leg, rebuilding with metal implants, bone grafts or growing prostheses in children.

Preserves function without compromising survival
Custom implants for pelvis and spine

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record

Limb-salvage surgery and endoprosthetic reconstruction

Implant infection and mechanical failure over decades
Requires specialist sarcoma centres

Questions to ask about this decision

Is Limb-salvage surgery and endoprosthetic reconstruction the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
Why: A single standard does not mean a single choice; timing and trials are decisions too.
What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
Why: The aim shapes how much side effect and disruption is worth accepting.
What happens if I delay, or decline this step for now? Is the decision reversible?
Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
For my situation (surgery), which of the standard options do you recommend and why?
Why: Guideline options include: Reserved for selected abdominal wall tumours or complications (bowel obstruction, fistula); margins do not reliably predict recurrence.

Add these to your appointment list, or take the full question set for this cancer.